“Coping with Caregiver Burnout When Caring for A Person with Neurodegenerative Disease: A Guide for Caregivers,” published in the April 2017 issue of the Archives for Physical Medicine and Rehabilitation, is intended to give better insight into caregiver burnout, and what might be…
Engaging Thoughts
— Laura Kolaczkowski
Laura Kolaczkowski comes from Beavercreek, Ohio, and worked at the University of Dayton for over 25 years until MS challenged her enough to go onto full-time disability. She is active in the MS community on multiple levels, and writes for her own personal blog, InsideMyStory and as a patient expert for MultipleSclerosis.net. Laura is the Lead Patient Representative and co-principal investigator for iConquerMS™, a patient powered MS research network. Laura freely admits her Liberal Arts background fuels her interest in patient engagement and empowerment and she struggles with the science of MS.
Featured Post
I love to travel and see new sights, but my multiple sclerosis (MS) mobility problems present particular challenges. Over time I have accumulated my own set of travel tips. Perhaps some of the following might make your next trip easier. Airline travel My trips almost always involve airline…
Laura Kolaczkowski -- Engaging Thoughts
I knew it was only a matter of time before my MS neurologist would have MS PATHS available to collect clinical data from people who have agreed to participate. MS PATHS is an information- and biological sample-gathering clinical study from Biogen, the leading manufacturer of multiple sclerosis disease-modifying…
The American Academy of Neurology‘s (AAN) 2017 annual meeting will bring together physicians who practice in all areas of neurology, including our own multiple sclerosis (MS) specialists. In a recent interview with Anthony Traboulsee, MD, associate professor and research chair of the MS Society of…
Pamela Arterbridge is one of 70 people at Ohio State University’s Multiple Sclerosis Center taking part in the open-label part of a clinical trial for ocrelizumab, now best known as Ocrevus. She is a patient of Dr. Michael Racke, who is a pioneer in the field of B-cell treatments for MS,…
A prominent neurologist, who was involved in early research into B-cell therapy, tells Multiple Sclerosis News Today about his positive experience of using ocrelizumab, now branded Ocrevus, with patients. Michael Racke, MD, Department of Neurology at The Ohio State University Wexner Medical Center took time to talk with me about…
Have you ever used acupuncture? I have a number of times and would do so more often if it were a medical service covered by my insurance. Unfortunately, for now, most complementary treatments we have available to help with the symptoms of multiple sclerosis are not covered by commercial insurance. In…
The sky-high costs to Medicare for prescriptions of the MS medication H.P. Acthar Gel, as reported in Multiple Sclerosis News Today were highlighted at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum in…
I was in Washington, D.C. for a meeting, and had the opportunity to dine with some fellow multiple sclerosis advocates. I thought it might be of interest to get their take on the most pressing issues of 2017 for people living with MS. I wasn’t sure what to…
The role of the microbiome and its association with multiple sclerosis was the topic of several sessions and papers at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum. More than 800 researchers and clinicians attended the second annual meeting in Orlando last week to hear…
Harold Weiner, MD, believes in using probiotics to help treat multiple sclerosis. He is such a believer that he did a presentation on the subject — “Probiotics in Multiple Sclerosis” — at the just-concluded Americas for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum in Orlando. The event…
Editor’s note: Columnist Laura Kolaczkowski writes from the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum in Orlando, Fla., (Feb. 23-25). Two MS disease-modifying therapies, Ocrevus (ocrelizumab) and Rituxan (rituximab) were featured in this year’s Kenneth P. Johnson, MD, Memorial Lecture…
Evidence supporting the use of Vitamin D for people with multiple sclerosis continues to grow but there remains many unanswered questions as well. Ellen Mowry, MD, Associate Professor of Neurology and Epidemiology at the Johns Hopkins MS Center, presented Vitamin D supplementation as disease modifying therapy, to participants at…
Explore More Columns
Discussion
Discussion
Discussion